SUNNYVALE, Calif., June 21, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Fundación de Cancer de Mama in México City (FUCAM) has treated 1,000 breast cancer patients with the TomoTherapy® System. The milestone was achieved less than 18 months after the center installed the technology, underscoring its value as a mainstream treatment option to maximize tumor control with low toxicities for the full range of breast cancer cases, from routine to complex.
For more information on the TomoTherapy System visit www.accuray.com.
"FUCAM is a large and busy center focused on providing the best possible care to women with breast cancer. We require a radiation therapy system which can keep pace with the demands of our clinic and enable us to deliver precise radiation to any tumor in the shortest amount of time possible," said Dra Judith Huerta Bahena, head of radiotherapy, Institute of Diseases of the Breast, FUCAM. "The TomoTherapy System helps us do just that with its TomoHelical™ and TomoDirect™ treatment modes. The System provides the flexibility we need to precisely conform the radiation dose to the shape of the tumor and significantly decrease dose to nearby healthy organs and tissues."
The TomoTherapy System is the only radiation system specifically designed for image-guided intensity-modulated radiation therapy (IG-IMRT). Leveraging a CT scanner-based platform, TomoHelical™ mode enables continuous delivery from 360 degrees around the patient with highly conformal and homogeneous dose to the tumor. A clinician can also choose to deliver treatment from specific fixed angles via TomoDirect™ mode. The system's unique architecture helps ensure the highest levels of precision, while minimizing dose to organs at risk. This is especially important for women diagnosed with cancer in the left breast, where the tumor may be close to critical organs such as the heart.
"We are proud of the incredible work FUCAM is pioneering in Mexico and their dedication to improving the care of women with breast cancer. Their treatment milestone was achieved in a very short amount of time, demonstrating the immense need for effective breast cancer treatment in Mexico," said Joshua H. Levine, president and chief executive officer of Accuray. "The TomoTherapy System provides versatility and efficiency in the treatment of breast cancer, enabling clinicians such as Dra Huerta and her team to provide an optimal treatment for more patients."
FUCAM is a civil partnership with a mission to provide diagnosis and treatment for breast cancer, particularly in the most vulnerable socioeconomic groups, and to promote education about early detection of breast cancer. It´s the first non-profit institution established in Mexico and in Latin America with services, equipment, and highly specialized personnel fully-trained on the treatment of diseases of the breast.
FUCAM developed one of the most important campaigns in Mexico to educate women on the importance of a screening mammography in the early detection of breast cancer. For more information on FUCAM visit www.fucam.org.mx/
About the TomoTherapy® System
The TomoTherapy® System is capable of treating all standard radiation therapy indications, in addition to complex cases such as total marrow irradiation. Radiation oncologists have treated many types of cancers with the TomoTherapy System, including breast, prostate, lung, head & neck and pediatric. The system efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity modulated radiation for optimal sparing of healthy tissue and critical structures.
Potential Radiation Therapy Side Effects
Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary; often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury and even death. Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), and the patient's general medical condition, to name a few. For more details about the side effects of your radiation therapy, and if treatment with an Accuray product is right for you, ask your doctor.
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's reports on Form 10-Q, filed on November 5, 2015 and February 1, 2016 and April 29, 2016, and the company's other filings with the SEC.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
+1 (408) 789-4426
+1 (781) 684-6680
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fucam-treats-1000-breast-cancer-patients-with-the-tomotherapy-system-300287587.html
SOURCE Accuray Incorporated